Novella Clinical and the Cardiovascular Research Foundation announced a preferred provider collaboration.
Novella Clinical, a Quintiles company, and the Cardiovascular Research Foundation announced a preferred provider collaboration that will offer a set of clinical trial services to developers of cardiovascular drugs and devices. Novella, is a full-service clinical research organization with specialization in cardiovascular medical device research, and the Cardiovascular Research Foundation Clinical Trials Center, the academic research organization of the Foundation, with its extensive group of cardiovascular physicians and core labs, will work together to provide sponsors comprehensive clinical research services-from preclinical to post-market studies.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.